

# AMBEY LABORATORIES LIMITED

CIN: U74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,  
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: [accountho@ambeylab.com](mailto:accountho@ambeylab.com)  
[www.ambeylab.com](http://www.ambeylab.com)

---

Date: 13.11.2024

To,

The Head – Listing & Compliance

National Stock Exchange of India Ltd.,

Exchange Plaza, C-1, Block G, Bandra Kurla Complex,

Bandra (E) Mumbai – 400 051

**Symbol: AMBEY**

**ISIN : INE0M3I01029**

**Sub: Intimation on comments made by the Board of Directors on Non-Compliance w.r.t Regulation 33 of SEBI (LODR) Regulations, 2015**

**Ref:** Letter (bearing number NSE/LIST/SOP/1210) dated November 06, 2024 from NSE;

Letter (bearing number NSE/LIST-SOP/COMB/FINES/1080) dated September 13, 2024 from NSE

Dear Sir/ Madam,

This is to inform you that pursuant to SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, the Board of Directors was apprised of the monetary fines imposed by the NSE vide their letter dated September 13, 2024 for non-compliance with SEBI requirements for submitting financial results, specifically under Regulation 33(3)(j) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by the SEBI Second Amendment Regulations, 2023 (effective July 15, 2023). A fine of ₹1,85,000 (plus 18% GST) was levied for a delay in filing financial results for the quarter or financial year immediately succeeding the period disclosed in the IPO offer document. According to the regulation, submissions are required within 45 days from the end of the half-year, 60 days from the financial year-end, or 21 days from the date of listing, whichever is later. The company has paid the fine of Rs. 2,18,300/- as specified in NSE's correspondence.

The Board acknowledges NSE's observations and reaffirms its commitment to fully complying with all regulatory requirements. Upon discovering the oversight, our team promptly submitted the required financials by September 7, 2024, and filed a waiver request to NSE explaining the circumstances. Although the waiver

# AMBEY LABORATORIES LIMITED

CIN: U74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,  
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: [accountho@ambeylab.com](mailto:accountho@ambeylab.com)  
[www.ambeylab.com](http://www.ambeylab.com)

---

was not granted, we have since strengthened our compliance protocols to prevent future occurrences, including reinforcing our compliance team and engaging external advisors for regulatory guidance.

The Board remains committed to upholding the highest standards of corporate governance and transparency and assures that prompt compliance with all regulatory obligations will be prioritized going forward.

Kindly take the above information on record and oblige.

Thanking You,

**For: AMBEY LABORATORIES LIMITED**

**Rimple Sarin**

**Designation: Company Secretary**

**Membership No: A66345**